Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii

This article belongs to the Special Issue Bacteriophage Treatment as an Alternative Technology to Inactivate Pathogenic Bacteria: A Generalized Worldwide Growing Acceptance.

Detalles Bibliográficos
Autores: Blasco, Lucía, Ambroa, Antón, López, María, Fernández-García, Laura, Bleriot, Inés, Trastoy, Rocío, Ramos-Vivas, José, Coenye, Tom, Fernández-Cuenca, Felipe, Vila, Jordi, Martínez-Martínez, Luis, Rodríguez-Baño, Jesús, Pascual, Álvaro, Cisneros, José Miguel, Pachón, Jerónimo, Bou, Germán, Tomás, María
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/214385
Acceso en línea:http://hdl.handle.net/10261/214385
Access Level:acceso abierto
Palabra clave:Acinetobacter baumannii
Multiresistant
Mutant lytic phage
Phage therapy
Antibiotic-phage synergy
id ES_9c8fcee34089c7b39d448be2ca618d3d
oai_identifier_str oai:digital.csic.es:10261/214385
network_acronym_str ES
network_name_str España
repository_id_str
spelling Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumanniiBlasco, LucíaAmbroa, AntónLópez, MaríaFernández-García, LauraBleriot, InésTrastoy, RocíoRamos-Vivas, JoséCoenye, TomFernández-Cuenca, FelipeVila, JordiMartínez-Martínez, LuisRodríguez-Baño, JesúsPascual, ÁlvaroCisneros, José MiguelPachón, JerónimoBou, GermánTomás, MaríaAcinetobacter baumanniiMultiresistantMutant lytic phagePhage therapyAntibiotic-phage synergyThis article belongs to the Special Issue Bacteriophage Treatment as an Alternative Technology to Inactivate Pathogenic Bacteria: A Generalized Worldwide Growing Acceptance.Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from Acinetobacter baumannii into a lytic phage (Ab105-2phiΔCI) that displayed antimicrobial activity against A. baumannii clinical strain Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010, Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs of respectively, 32 µg/mL, and 16 µg/mL were obtained). We observed an in vitro synergistic antimicrobial effect (reduction of 4 log–7 log CFU/mL) between meropenem and the lytic phage in all combinations analyzed (Ab105-2phiΔCI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8 MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem at 1/4 MIC plus lytic phage (Ab105-2phiΔCI mutant) and by 4 log CFU/mL for the combination of imipenem at 1/8 MIC plus lytic phage (Ab105-2phiΔCI mutant) at both MOI 1 and 10. These results were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant Ab105-2phiΔCI was most effective (p < 0.05). This approach could help to reduce the emergence of phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of Acinetobacter baumannii.This study was funded by grant PI16/01163 awarded to M. Tomás within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (REIPI, RD16/0016/0001, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0009 and RD16/0016/0010) and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC, http://www.seimc.org/). M. Tomás was financially supported by SERGAS (ACIS, Axencia de Conecemento en Saude, Xunta de Galicia). R. Trastoy and L. Fernández-García were financially supported by respectively an SEIMC grant and a fellowship from the Deputacion Provincial da Coruña, Xunta de Galicia.Multidisciplinary Digital Publishing InstituteMinisterio de Ciencia e Innovación (España)Instituto de Salud Carlos IIIEuropean CommissionRed Española de Investigación en Patología InfecciosaXunta de GaliciaSociedad Española de Enfermedades Infecciosas y Microbiología ClínicaDeputación Provincial da CoruñaConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2020202020192020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/214385reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.3390/microorganisms7110556Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2143852026-05-22T06:33:51Z
dc.title.none.fl_str_mv Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
title Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
spellingShingle Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
Blasco, Lucía
Acinetobacter baumannii
Multiresistant
Mutant lytic phage
Phage therapy
Antibiotic-phage synergy
title_short Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
title_full Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
title_fullStr Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
title_full_unstemmed Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
title_sort Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii
dc.creator.none.fl_str_mv Blasco, Lucía
Ambroa, Antón
López, María
Fernández-García, Laura
Bleriot, Inés
Trastoy, Rocío
Ramos-Vivas, José
Coenye, Tom
Fernández-Cuenca, Felipe
Vila, Jordi
Martínez-Martínez, Luis
Rodríguez-Baño, Jesús
Pascual, Álvaro
Cisneros, José Miguel
Pachón, Jerónimo
Bou, Germán
Tomás, María
author Blasco, Lucía
author_facet Blasco, Lucía
Ambroa, Antón
López, María
Fernández-García, Laura
Bleriot, Inés
Trastoy, Rocío
Ramos-Vivas, José
Coenye, Tom
Fernández-Cuenca, Felipe
Vila, Jordi
Martínez-Martínez, Luis
Rodríguez-Baño, Jesús
Pascual, Álvaro
Cisneros, José Miguel
Pachón, Jerónimo
Bou, Germán
Tomás, María
author_role author
author2 Ambroa, Antón
López, María
Fernández-García, Laura
Bleriot, Inés
Trastoy, Rocío
Ramos-Vivas, José
Coenye, Tom
Fernández-Cuenca, Felipe
Vila, Jordi
Martínez-Martínez, Luis
Rodríguez-Baño, Jesús
Pascual, Álvaro
Cisneros, José Miguel
Pachón, Jerónimo
Bou, Germán
Tomás, María
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia e Innovación (España)
Instituto de Salud Carlos III
European Commission
Red Española de Investigación en Patología Infecciosa
Xunta de Galicia
Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Deputación Provincial da Coruña
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Acinetobacter baumannii
Multiresistant
Mutant lytic phage
Phage therapy
Antibiotic-phage synergy
topic Acinetobacter baumannii
Multiresistant
Mutant lytic phage
Phage therapy
Antibiotic-phage synergy
description This article belongs to the Special Issue Bacteriophage Treatment as an Alternative Technology to Inactivate Pathogenic Bacteria: A Generalized Worldwide Growing Acceptance.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/214385
url http://hdl.handle.net/10261/214385
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.3390/microorganisms7110556
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414669131710464
score 15.81155

Similares en LA Referencia